Apollomics
Foster City, California, United States · Biopharma, Biotechnology, Health Care
Apollomics is an innovative biotechnology company committed to the discovery and development of oncology combination therapies. With operations in both the U.S. and China, we believe we are well positioned to unlock synergies by leveraging the strengths of partnerships with other biotechnology companies in the East and the West.
Key facts
- Headquarters
- Foster City, California, United States
- Employees
- 51
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (APLM)
- Website
- apollomics.com
- Company page
Recent activity at Apollomics
Apollomics funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Venture | $10.0M |
Leadership
- Kun-Po, Director of Business Development
- Hugh, Vice President, Head of CMC
- Mythili, Head of Drug Safety, Pharmacovigilance and Risk Management
- Matthew Plunkett, Chief Financial Officer
Verified email and direct lines for Apollomics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Apollomics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Apollomics in the news
- Monday’s insider activity: Major buys at Cardinal, Apollomics - Investing.com (Aug 18, 2026)
- Apollomics Announces $10 Million Private Placement Transaction - GlobeNewswire (Aug 11, 2026)
- Insiders Of Apollomics Are Up 69% On Their US$7.95m Purchase - Simply Wall Street (Aug 19, 2026)
- Apollomics Inc. Announces $2.0 Million Bridge Financing - Yahoo Finance (Apr 01, 2026)
- Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress - GlobeNewswire (Apr 27, 2026)
- Apollomics hands Asia rights to its lead c-MET inhibitor to Taiwan’s LaunXP in $60M deal - Fierce Biotech (Mar 31, 2025)
- White & Case advises Apollomics Inc. on its US$899 million business combination with Maxpro Capital Acquisition Corp. - White & Case LLP (Sep 14, 2022)
- Apollomics: APLM Stock Price Quote & News - Robinhood (Jan 20, 2024)
Companies similar to Apollomics
- Day One Biopharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- CASI Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Zai Lab Limited & MediLink Therapeutics (Suzhou) Ltd · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- BridgeBio Oncology Therapeutics · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Windward Bio · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
About Apollomics: questions and answers
What does Apollomics do?
Apollomics is an innovative biotechnology company committed to the discovery and development of oncology combination therapies. With operations in both the U.S. and China, we believe we are well positioned to unlock synergies by leveraging the strengths of partnerships with other biotechnology companies in the East and the West.
Where is Apollomics headquartered?
Apollomics is headquartered in Foster City, California, United States.
How many employees does Apollomics have?
Apollomics has about 51 employees.
Has Apollomics raised funding?
Yes. Fundz has recorded 1 funding event for Apollomics. The most recent, $10.0M, was in Aug 2026.
Who leads Apollomics?
Hugh is a Vice President, Head of CMC at Apollomics.
What is the latest news on Apollomics?
On Aug 19, 2026, Apollomics
Is Apollomics a public company?
Yes. Apollomics is publicly traded under the ticker APLM.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy